These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 9207936

  • 21. Scaffold-hopping cascade yields potent inhibitors of 5-lipoxygenase.
    Hofmann B, Franke L, Proschak E, Tanrikulu Y, Schneider P, Steinhilber D, Schneider G.
    ChemMedChem; 2008 Oct; 3(10):1535-8. PubMed ID: 18688907
    [No Abstract] [Full Text] [Related]

  • 22. Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling.
    Zheng M, Zheng M, Ye D, Deng Y, Qiu S, Luo X, Chen K, Liu H, Jiang H.
    Bioorg Med Chem Lett; 2007 May 01; 17(9):2414-20. PubMed ID: 17336065
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.
    Uto Y, Ogata T, Harada J, Kiyotsuka Y, Ueno Y, Miyazawa Y, Kurata H, Deguchi T, Watanabe N, Takagi T, Wakimoto S, Okuyama R, Abe M, Kurikawa N, Kawamura S, Yamato M, Osumi J.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4151-8. PubMed ID: 19540759
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate.
    Wood J, Bagi CM, Akuche C, Bacchiocchi A, Baryza J, Blue ML, Brennan C, Campbell AM, Choi S, Cook JH, Conrad P, Dixon BR, Ehrlich PP, Gane T, Gunn D, Joe T, Johnson JS, Jordan J, Kramss R, Liu P, Levy J, Lowe DB, McAlexander I, Natero R, Redman AM, Scott WJ, Town C, Wang M, Wang Y, Zhang Z.
    Bioorg Med Chem Lett; 2006 Sep 15; 16(18):4965-8. PubMed ID: 16806919
    [Abstract] [Full Text] [Related]

  • 28. Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor.
    Shirumalla RK, Sharma P, Dastidar SG, Paliwal JK, Kakar S, Varshney B, Singh Saini G, Sattigeri V, Salman M, Ray A.
    Inflamm Res; 2008 Mar 15; 57(3):135-43. PubMed ID: 18369577
    [Abstract] [Full Text] [Related]

  • 29. Binding investigation of human 5-lipoxygenase with its inhibitors by SPR technology correlating with molecular docking simulation.
    Du L, Zhang Z, Luo X, Chen K, Shen X, Jiang H.
    J Biochem; 2006 Apr 15; 139(4):715-23. PubMed ID: 16672272
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Discovery of a new chemical lead for a matrix metalloproteinase inhibitor.
    Ikura M, Nakatani S, Yamamoto S, Habashita H, Sugiura T, Takahashi K, Ogawa K, Ohno H, Nakai H, Toda M.
    Bioorg Med Chem; 2006 Jun 15; 14(12):4241-52. PubMed ID: 16481176
    [Abstract] [Full Text] [Related]

  • 32. 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.
    Tripathy R, Ghose A, Singh J, Bacon ER, Angeles TS, Yang SX, Albom MS, Aimone LD, Herman JL, Mallamo JP.
    Bioorg Med Chem Lett; 2007 Mar 15; 17(6):1793-8. PubMed ID: 17239587
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs).
    Chen QH, Rao PN, Knaus EE.
    Bioorg Med Chem; 2006 Dec 01; 14(23):7898-909. PubMed ID: 16904331
    [Abstract] [Full Text] [Related]

  • 39. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P.
    J Med Chem; 1997 Oct 24; 40(22):3601-16. PubMed ID: 9357527
    [Abstract] [Full Text] [Related]

  • 40. Glucuronidation of zileuton (A-64077) by human hepatic microsomes.
    Sweeny DJ, Bouska J, Machinist J, Bell R, Carter G, Cepa S, Nellans HN.
    Drug Metab Dispos; 1992 Oct 24; 20(2):328-9. PubMed ID: 1352229
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.